RT Journal Article
SR Electronic
T1 The use of betablockers in chronic airway disease causing acute respiratory failure in intensive care unit
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2428
VO 42
IS Suppl 57
A1 Feyza Kargin
A1 Huriye Berk Takir
A1 Can Yücel Karabay
A1 Cüneyt Saltürk
A1 Nezihe Çiftaslan Göksenoglu
A1 Ozlem Yazicioglu Mocin
A1 Gokay Gungor
A1 Nalan Adiguzel
A1 Merih Kalamanoglu Balci
A1 Ramazan Kargin
A1 Zuhal Karakurt
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P2428.abstract
AB Introduction:Data about safe use of beta blockers as rate limiter drugs (RLD) in patients with acute respiratory failure due to chronic airway disease is controversial.Aim: To investigate is there any difference between intensive care unit (ICU) results of using beta blockers or non-beta blockers as RLD in patients with acute respiratory failure (ARF).Material and method: Retrospective (January 2011-December 2012) observational cohort study in ICU of tertiary training hospital. Patients having ARF because of CAD and using rate limiting drug were included. Demographics, reason for RLD use, cause of ARF ,comorbitities, APACHE II score, application and duration of noninvasive or invasive mechanical ventilation ,heart rate,CRP levels,biochemistry values and complete blood count,length of ICU stay,and mortality were recorded.Patients were divided in two groups as group 1(using only beta blocker as RLD) and Group 2 (using drugs other than beta blocker).Results:188 patients (46 female) enrolled to study. Age, gender, co-morbities, duration and type of MV application were similar between Group 1(n=74) and Group 2(n=114).Reasons for RLD use were different between two groups.Atrial fibrillation 23% and %30, supraventricular tachycardia 41.9 % and 54.4%, congestive heart failure 17.6% and 4.4% for Group 1 and 2 respectively.Median length of ICU stay (6[4-10] and 7[4-10] day p=0.70),APACHE II score (19[17-23]) and 20[16-24] p=0.88),mortality (n=13 17.6% and n=18 15.8% p=0.75) were also similar.Conclusion: In chronic airway disease, despite the development of ARF, there is no difference between outcomes of use of beta blockers and other RLD for treatment of tachycardia.